Evidence map›Paper›PMID 42418948›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2026

Mechanistically resolved prediction of compound hepatotoxicity using primary human liver spheroids-Application to recent real-world cases.

Yufeng Li, Hongda Sheng, Tingting Zhou, Chen Xing, Miriam Kukasch, Siyuan Shao, Sonia Youhanna, Sabine U Vorrink, Yingxin Liang, Anne T Nies and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Yufeng LiCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Hongda ShengCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China; National Key Laboratory of Chinese Medicine Modernization, Innovation Center of Yangtze River Delta, Zhejiang University, Jiaxing, China.
Tingting ZhouShanghai Hepo Biotechnology Co, Ltd, Shanghai, China.
Chen XingDr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany; Department of Physiology and Pharmacology and Center for Molecular Medicine, Karolinska Institutet and University Hospital, Stockholm, Sweden.
Miriam KukaschDr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany.
Siyuan ShaoShanghai Hepo Biotechnology Co, Ltd, Shanghai, China.
Sonia YouhannaHepaPredict AB, Stockholm, Sweden.
Sabine U VorrinkHepaPredict AB, Stockholm, Sweden.
Yingxin LiangCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China; Department of Physiology and Pharmacology and Center for Molecular Medicine, Karolinska Institutet and University Hospital, Stockholm, Sweden.
Anne T NiesDr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany.
Julia DresslerDr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany.
Charlotte KölzDr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany.
Jinhye RyuDepartment of Physiology and Pharmacology and Center for Molecular Medicine, Karolinska Institutet and University Hospital, Stockholm, Sweden.
Nayere TaebniaDepartment of Physiology and Pharmacology and Center for Molecular Medicine, Karolinska Institutet and University Hospital, Stockholm, Sweden.
Dominik JacobDepartment of Drug Metabolism and Pharmacokinetics (DMPK), the Healthcare Business of Merck KGaA, Darmstadt, Germany.
Caroline HauserDr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany.
Carl PeterssonDepartment of Drug Metabolism and Pharmacokinetics (DMPK), the Healthcare Business of Merck KGaA, Darmstadt, Germany.
Kathrin KleinDr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany.
Oliver BurkDr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany.
Boxu ShiThe Chinese University of Hong Kong, Shenzhen, China.
Qiaojun HeCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Volker M LauschkeDr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany; Department of Physiology and Pharmacology and Center for Molecular Medicine, Karolinska Institutet and University Hospital, Stockholm, Sweden; Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China. Electronic address: volker.lauschke@ki.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced liver injury remains a major cause of clinical trial attrition and postmarketing drug withdrawals, reflecting persistent translational gaps in predictive preclinical models of compound hepatotoxicity. Here, we applied a well-characterized 3-dimensional primary human liver spheroid platform to interrogate diverse mechanisms of hepatotoxicity and benchmark performance against recent real-world clinical cases. After multicenter technology transfer, spheroids maintained stable hepatic functionality, including expression of metabolic enzymes and transporters, albumin secretion, and long-term CYP activity. Importantly, repeated-dose exposure to established hepatotoxins demonstrated robust, concentration-dependent toxicity with excellent interexperimental (R

Indexed as

Chemical and Drug Induced Liver InjuryHepatocytesLiverSpheroids, CellularBosentanCells, CulturedChlorpromazineHumansMitochondria, LiverBosentanChlorpromazine3D spheroidsDrug-induced liver injuryMitochondrial toxicityRetrospective validationTranslational safety

Identifiers

PMID42418948
PMCPMC13688977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.